A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial
-
- F. A. Shepherd
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
-
- J. Pereira
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
-
- T. E. Ciuleanu
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
-
- E. H. Tan
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
-
- V. Hirsh
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
-
- S. Thongprasert
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
-
- A. Bezjak
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
-
- D. Tu
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
-
- P. Santabárbara
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
-
- L. Seymour
- NCIC CTG, Kingston, ON, Canada; OSI Pharmaceuticals, Boulder, CO
収録刊行物
-
- Journal of Clinical Oncology
-
Journal of Clinical Oncology 22 (14_suppl), 7022-7022, 2004-07-15
American Society of Clinical Oncology (ASCO)